Curcumin sensitizes glioblastoma to temozolomide by simultaneously generating ROS and disrupting AKT/mTOR signaling

Oncology Reports

Volumn 32, Issue 4, 2014, Pages 1610-1616

  Yin, Haitao ^a   Zhou, Yun ^a   Wen, Cuixia ^a   Zhou, Chong ^a   Zhang, Wei ^a   Hu, Xiang ^a   Wang, Lifeng ^b   You, Chuanwen ^c   Shao, Junfei ^d  

^a SOUTHEAST UNIVERSITY   (China)

^b NANJING UNIVERSITY   (China)

^c Suqian People's Hospital   (China)

^d NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Curcumin; Glioblastoma; Protein kinase B mammalian target of rapamycin; Reactive oxygen species; Sensitization; Temozolomide

Indexed keywords

CURCUMIN; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAD; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; TEMOZOLOMIDE; ANTINEOPLASTIC AGENT; DACARBAZINE; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DRUG POTENTIATION; DRUG RESPONSE; DRUG SENSITIZATION; EXCISION REPAIR; GLIOBLASTOMA; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SURVIVAL TIME; TUMOR VOLUME; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANIMAL; CELL SURVIVAL; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; METABOLISM; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; CURCUMIN; DACARBAZINE; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; GLIOBLASTOMA; HUMANS; MICE; PROTO-ONCOGENE PROTEINS C-AKT; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84921650071     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3342     Document Type: Article

References (29)

1. Stupp R, Mason WP, van den Bent MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996, 2005. (Pubitemid 40349501)
2. DeAngelis LM: Brain tumors. N Engl J Med 344: 114-123, 2001.
3. Laws ER, Parney IF, Huang W, et al: Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. J Neurosurg 99: 467-473, 2003. (Pubitemid 37040405)
4. Kapoor R, Revesz T and Powell M: Solitary cervical lymphoma presenting as a neurofibroma. Br J Neurosurg 6: 583-586, 1992. (Pubitemid 23023488)
5. Perry JR, Bélanger K, Mason WP, et al: Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J Clin Oncol 28: 2051-2057, 2010.
6. Mirimanoff RO, Gorlia T, Mason W, et al: Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol 24: 2563-2569, 2006. (Pubitemid 46630635)
7. Mrugala MM and Chamberlain MC: Mechanisms of disease: temozolomide and glioblastoma - look to the future. Nat Clin Pract Oncol 5: 476-486, 2008.
8. Kohsaka S, Wang L, Yachi K, et al: STAT3 inhibition overcomes temozolomide resistance in glioblastoma by downregulating MGMT expression. Mol Cancer Ther 11: 1289-1299, 2012.
9. Kohsaka S, Takahashi K, Wang L, et al: Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma. Cancer Lett 331: 68-75, 2013.
10. Joe B, Vijaykumar M and Lokesh BR: Biological properties of curcumin-cellular and molecular mechanisms of action. Crit Rev Food Sci Nutr 44: 97-111, 2004. (Pubitemid 38552286)
11. Maheshwari RK, Singh AK, Gaddipati J and Srimal RC: Multiple biological activities of curcumin: a short review. Life Sci 78: 2081-2087, 2006.
12. Kunnumakkara AB, Anand P and Aggarwal BB: Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett 269: 199-225, 2008.
13. Das T, Sa G, Saha B and Das K: Multifocal signal modulation therapy of cancer: ancient weapon, modern targets. Mol Cell Biochem 336: 85-95, 2010.
14. Basile V, Ferrari E, Lazzari S, Belluti S, Pignedoli F and Imbriano C: Curcumin derivatives: molecular basis of their anticancer activity. Biochem Pharmacol 78: 1305-1315, 2009.
15. Hussain AR, Al-Rasheed M, Manogaran PS, et al: Curcumin induces apoptosis via inhibition of PI3′-kinase/AKT pathway in acute T cell leukemias. Apoptosis 11: 245-254, 2006. (Pubitemid 43291024)
16. Zheng S and Chen A: Activation of PPARgamma is required for curcumin to induce apoptosis and to inhibit the expression of extracellular matrix genes in hepatic stellate cells in vitro. Biochem J 384: 149-157, 2004. (Pubitemid 39564171)
17. Lu JJ, Cai YJ and Ding J: The short-time treatment with curcumin sufficiently decreases cell viability, induces apoptosis and copper enhances these effects in multidrug-resistant K562/A02 cells. Mol Cell Biochem 360: 253-260, 2012.
18. Ramachandran C, Nair SM, Escalon E and Melnick SJ: Potentiation of etoposide and temozolomide cytotoxicity by curcumin and turmeric force in brain tumor cell lines. J Complement Integr Med 9: Article 20, 2012.
19. Chen CC, Taniguchi T and D'Andrea A: The Fanconi anemia (FA) pathway confers glioma resistance to DNA alkylating agents. J Mol Med 85: 497-509, 2007. (Pubitemid 46701659)
20. Roos WP, Batista LF, Naumann SC, et al: Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine. Oncogene 26: 186-197, 2007. (Pubitemid 46095730)
21. Lin CJ, Lee CC, Shih YL, et al: Resveratrol enhances the therapeutic effect of temozolomide against malignant glioma in vitro and in vivo by inhibiting autophagy. Free Radic Biol Med 52: 377-391, 2012.
22. Sánchez Y, Simón GP, Calviño E, de Blas E and Aller P: Curcumin stimulates reactive oxygen species production and potentiates apoptosis induction by the antitumor drugs arsenic trioxide and lonidamine in human myeloid leukemia cell lines. J Pharmacol Exp Ther 335: 114-123, 2010.
23. 2 arrest and protects from temozolomide-induced mitotic catastrophe and cellular senescence. Cancer Res 65: 4861-4869, 2005.
24. Chen L, Han L, Shi Z, et al: LY294002 enhances cytotoxicity of temozolomide in glioma by down-regulation of the PI3K/Akt pathway. Mol Med Rep 5: 575-579, 2012.
25. Yu S, Shen G, Khor TO, Kim JH and Kong AN: Curcumin inhibits Akt/mammalian target of rapamycin signaling through protein phosphatase- dependent mechanism. Mol Cancer Ther 7: 2609-2620, 2008.
26. Datta SR, Dudek H, Tao X, et al: Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91: 231-241, 1997. (Pubitemid 27456390)
27. Zhang J, Stevens MF and Bradshaw TD: Temozolomide: mechanisms of action, repair and resistance. Curr Mol Pharmacol 5: 102-114, 2012.
28. Gupta SC, Patchva S, Koh W and Aggarwal BB: Discovery of curcumin, a component of golden spice, and its miraculous biological activities. Clin Exp Pharmacol Physiol 39: 283-299, 2012.
29. Hegi ME, Diserens AC, Gorlia T, et al: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352: 997-1003, 2005. (Pubitemid 40349502)